Von Hippel-Lindau disease

From Wikipedia, the free encyclopedia

Von Hippel-Lindau disease
Classification and external resources
ICD-10 Q85.8
ICD-9 759.6
OMIM 193300
DiseasesDB 14000
eMedicine ped/2417  oph/354
MeSH C10.562.400

Von Hippel-Lindau disease (VHL) is a rare inherited genetic condition involving the abnormal growth of tumors in parts of the body which are particularly rich in blood supply.

Contents

[edit] Features

Features of VHL are:

Untreated, VHL may result in blindness and permanent brain damage; death is usually caused by complications of tumors in the brain or kidney, cardiovascular disease secondary to pheochromocytoma. With early detection and appropriate treatment, there is more hope today for people with VHL than ever before.

[edit] Types

There are various subtypes:

  • Type 1 (angiomatosis without pheochromocytoma)
  • Type 2 (angiomatosis with pheochromocytoma)
    • Type 2A (low risk of renal cell carcinoma)
    • Type 2B (high risk of renal cell carcinoma)
    • Type 2C (only pheochromocytoma and no angiomatosis or renal cell carcinoma)

[edit] Genetics

The disease is caused by mutations of the Von Hippel-Lindau tumor suppressor (VHL) gene on the short arm of third chromosome.

Von Hippel-Lindau disease is inherited in an autosomal dominant pattern.
Von Hippel-Lindau disease is inherited in an autosomal dominant pattern.

VHL is an autosomal dominant disorder, but there is a wide variation in the age of onset of the disease, the organ system affected and the severity of effect. Most people with von Hippel-Lindau syndrome inherit an altered copy of the gene from one parent. In about 20 percent of cases, however, the altered gene is the result of a new mutation that occurred during the formation of reproductive cells (eggs or sperm) or early in fetal development.

As long as one copy of the VHL gene is producing functional VHL protein in each cell, tumors do not form. If a mutation occurs in the second copy of the VHL gene during a person's lifetime, the cell will have no working copies of the gene and will produce no functional VHL protein. A lack of this protein allows tumors characteristic of von Hippel-Lindau syndrome to develop.

[edit] History

Eugen von Hippel described the angiomas in the eye in 1904.[1]. Arvid Lindau described the angiomas of the cerebellum and spine in 1927.[2]

In an article appearing in the Associated Press, it has been speculated by a Vanderbilt University endocrinologist that the hostility underlying the Hatfield-McCoy feud may have been partly due to the consequences of Von Hippel-Lindau disease. The article suggests that the McCoy family was pre-disposed to bad tempers because many of them had a pheochromocytoma, which produced excess adrenaline and a tendency toward explosive tempers.[3] Pheochromocytomas produce surges of adrenaline which are more often perceived as panic attacks than rage attacks. Left untreated, they will cause serious cardiovascular disease, heart attack, and stroke. Only about 20% of people with VHL get pheochromocytomas.[4]

[edit] Nomenclature

Other names are: angiomatosis retinae, angiophakomatosis retinae et cerebelli, familial cerebello-retinal angiomatosis, cerebelloretinal hemangioblastomatosis, Hippel Disease, Hippel-Lindau syndrome, HLS, Lindau disease or retinocerebellar angiomatosis.

[edit] See also

[edit] References

  1. ^ Von Hippel E. Ueber eine sehr seltene Erkrankung der Netzhaut. Albrecht von Graefes Arch Ophthal 1904;59:83-106.
  2. ^ Lindau A. Zur Frage der Angiomatosis Retinae und Ihrer Hirncomplikation. Acta Ophthal 1927;4:193-226.
  3. ^ "Hatfield-McCoy feud blamed on ‘rage’ disease", MSNBC.com, 2007-04-05. Retrieved on 2007-04-05. 
  4. ^ "'Pheochromocytoma Information'", vhl.org, 2007-04-05. Retrieved on 2007-04-05. 

[edit] External links

v • d • e
Phakomatoses (Q85, 759.5-759.6)
Neurofibromatosis
Other